Metabolic syndrome and sexual dysfunction

Current Opinion in Urology

Volumn 21, Issue 6, 2011, Pages 514-518

  Chughtai, Bilal ^a   Lee, Richard K ^a   Te, Alexis E ^a   Kaplan, Steven A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

erectile dysfunction; metabolic syndrome; sexual dysfunction; syndrome X

Indexed keywords

ANASTROZOLE; ATAMESTANE; CLOMIFENE CITRATE; LETROZOLE; SILDENAFIL; TADALAFIL; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ANDROGEN THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; HUMAN; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; UNSPECIFIED SIDE EFFECT;

ERECTILE DYSFUNCTION; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; PENILE ERECTION; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 80054001353     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32834b8681     Document Type: Review

References (50)

1. WHO Consultation on Obesity. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 296:E1230.
2. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. J Am Med Assoc 2002; 288:1723.
3. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med 2003; 163:2146.
4. Ruhm C. Current and future prevalence of obesity and severe obesity in the United States. In NBER Working Paper No 13181; 2007.
5. Golden SH, Robinson KA, Saldanha I, et al. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94:1853.
6. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009; 2:231.
7. Corona G, Mannucci E, Petrone L, et al. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndromeassociated sexual dysfunction. J Sex Med 2007; 4:789.
8. Heidler S, Temml C, Broessner C, et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol 2007; 177:651.
9. Bal K, Oder M, Sahin AS, et al. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology 2007; 69:356.
10. Demir T, Demir O, Kefi A, et al. Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Urol 2006; 13:385.
11. Kupelian V, Shabsigh R, Araujo AB, et al. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol 2006; 176:222.
12. Corona G, Mannucci E, Ricca V, et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 2009; 32:720.
13. Reilly CM, Zamorano P, Stopper VS, et al. Androgenic regulation of NO availability in rat penile erection. J Androl 1997; 18:110.
14. Blumentals WA, Gomez-Caminero A, Joo S, et al. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 2004; 16:350.
15. Beckman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001; 103:1618.
16. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404:787.
17. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003; 108:1527.
18. Jiaan DB, Seftel AD, Fogarty J, et al. Age-related increase in an advanced glycation end product in penile tissue. World J Urol 1995; 13:369.
19. Bemelmans BL, Meuleman EJ, Doesburg WH, et al. Erectile dysfunction in diabetic men: the neurological factor revisited. J Urol 1994; 151:884.
20. Vermeulen A. Androgen replacement therapy in the aging male: a critical evaluation. J Clin Endocrinol Metab 2001; 86:2380.
21. Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients: 2002 update. Endocr Pract 2002; 8:440.
22. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89:3813.
23. Kupelian V, Hayes FJ, Link CL, et al. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab 2008; 93:3403.
24. Goncharov NP, Katsya GV, Chagina NA, et al. Three definitions of metabolic syndrome applied to a sample of young obese men and their relation with plasma testosterone. Aging Male 2008; 11:118.
25. Kapoor D, Clarke S, Stanworth R, et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156:595.
26. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009; 296:E1230.
27. McConway MG, Johnson D, Kelly A, et al. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann Clin Biochem 2000; 37:717.
28. Caprio M, Isidori AM, Carta AR, et al. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 1999; 140:4939.
29. Luukkaa V, Pesonen U, Huhtaniemi I, et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998; 83:3243.
30. Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14:226.
31. Vermeulen A, Kaufman JM, Deslypere JP, et al. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993; 76:1140.
32. Cohen PG. Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 2008; 70:358.
33. Kupelian V, Page ST, Araujo AB, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91:843.
34. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.
35. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. J Am Med Assoc 2004; 291:2978.
36. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc 2003; 289:1799.
37. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338:1397.
38. Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60:12.
39. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168:1332.
40. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154:899.
41. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6:1.
42. Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009; 296:E1230.
43. Raven G, de Jong FH, Kaufman JM, et al. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 2006; 91:3324.
44. Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008; 158:741.
45. Leder BZ, Rohrer JL, Rubin SD, et al. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab 2004; 89:1174.
46. Muller M, van den Beld AW, van der Schouw YT, et al. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J Clin Endocrinol Metab 2006; 91:3988.
47. Guay AT, Jacobson J, Perez JB, et al. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res 2003; 15:156.
48. Guay AT, Perez JB, Fitaihi WA, et al. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pract 2000; 6:132.
49. Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebocontrolled trial with clomiphene citrate. J Clin EndocrinolMetab 1995; 80:3546.
50. Shabsigh A, Kang Y, Shabsign R, et al. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J Sex Med 2005; 2:716.